Teva Pharma (TEVA) Lowers Quarterly Dividend 75% to $0.085; 1.1% Yield

Go back to Teva Pharma (TEVA) Lowers Quarterly Dividend 75% to $0.085; 1.1% Yield

Credit Suisse Downgrades Teva Pharma (TEVA) to Neutral

August 4, 2017 6:01 AM EDT

Credit Suisse downgraded Teva Pharma (NYSE: TEVA) from Outperform to Neutral with a price target of $25.00 (from $39.00).

Analyst Vamil Divan said as they look ahead they believe there are still no signs of stabilization for some of the key issues impacting TEVAs core... More

Teva Pharma (TEVA) Cracks Fresh Low, Now Down 19.65%

August 3, 2017 11:17 AM EDT

Teva Pharma (NYSE: TEVA) Cracks Fresh Low, Now Down 19.65%

... More

Teva Pharma (TEVA) Sinks 16% on Weak Results, Outlook

August 3, 2017 8:18 AM EDT

Teva Pharma (NYSE: TEVA) shares sink nearly 16% in pre-open trade following weak results and outlook.

... More

Teva Pharma (TEVA) Misses Q2 EPS by 4c, Lowers FY EPS Guidance, Cuts Dividend

August 3, 2017 6:33 AM EDT

(Updated - August 3, 2017 6:40 AM EDT)

Teva Pharma (NYSE: TEVA) reported Q2 EPS of $1.02, $0.04 worse than the analyst estimate of $1.06. Revenue for the quarter came in at $5.7 billion versus the consensus estimate of $5.76 billion.

GUIDANCE:

Teva Pharma sees Q3 2017 EPS of $4.30-$4.50, versus the consensus of $4.74.

We... More